

A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease

NCT07113262

Status	RECRUITING
Phase	Phase 3
Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Enrollment	111 participants

Key Eligibility Criteria

Inclusion (5)

- At screening and baseline, the following diagnostic criteria for inactive TED were met:
- CAS of both eyes ≥ 2 points during the screening period and baseline;
- According to the subject's medical history, CAS of both eyes ≥ 2 points at least 6 months before screening, or according to the subject's chief complaint or medical history, with all of the following characteristics: no progression of proptosis and no new diplopia caused by TED at least 6 months before screening or no progression of diplopia caused by TED and no new inflammatory TED symptoms;
- According to the subject's chief complaint or medical history, the first TED diagnosis before screening was ≤ 2 years and < 10 years.
- At baseline, the proptosis of the study eye was ≤ 20 mm. 3.If the subject is a female, she should be infertile or have a negative blood pregnancy test during the screening period and agree to take contraceptive measures from the screening period to 120 days after the last medication. If the subject is a male, he should agree to take contraceptive measures from the screening period to 120 days after the last medication.

Exclusion (26)

- Subjects who meet any of the following conditions will not be eligible to participate in this study:
- At baseline, the eyeball protrusion of the study eye decreased by ≥ 2 mm compared with the screening period;
- Subjects who have been previously diagnosed with DON, or who are determined by the investigator to have DON during screening (defined as: orbital MRI/CT showing orbital apex crowding or optic nerve compression, and at least 2 of the following ophthalmological examination abnormalities that cannot be explained by other reasons: ` best corrected visual acuity $\setminus [BCVA] < 0.8$ or BCVA decreased by ≥ 2 lines compared with before the onset; a abnormal pupillary light reflex or relative pupillary afferent disorder; b color vision abnormalities; c optic disc edema and optic disc pallor on fundus examination; d visual field loss; e visual evoked potential with prolonged latency and/or decreased amplitude);
- Patients with corneal ulcers that are judged by the researchers to have no relief after treatment;
- Planned to receive orbital radiotherapy or surgical treatment for TED (including orbital decompression, strabismus correction, eyelid correction, etc.) at any time before baseline or during the study period;

... and 21 more (see full listing online)

Locations (1 total)

The First Affiliated Hospital of Medical University, Shenyang, Liaoning, China

<https://clinicaltrials.gov/study/NCT07113262>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).